On February 29, 2016 PeptiMimesis reported the inception and launch of its activities to develop a novel class of therapeutic peptides using a breakthrough technology from the University of Strasbourg and INSERM (French Institute of Health and Medical Research) (Press release, PeptiMimesis, FEB 29, 2016, View Source [SID:1234509510]). PeptiMimesis will now apply this cutting edge approach to a first set of 60 targets including the most promising in the chosen therapeutic areas.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Over the past 2 years, the techtransfer office SATT Conectus supported the team to develop the technology up to the proof of concept. PeptiMimesis was founded by three academic researchers, each having more than 15 years of experience in the field of transmembrane peptides, and Domain Therapeutics, a drug discovery company with a long and successful track record in targeting membrane receptors.

"This new venture highlights the quality of the incubation phase conducted by SATT Conectus and the high standard of research carried out by the University of Strasbourg and INSERM," said Pascal Neuville, CEO of Domain Therapeutics.

"The creation of PeptiMimesis is the culmination of many years of work developing our technology," said Dr Dominique Bagnard, founder. "With my two long – standing collaborators and co – founders, Dr Gérard Crémel and Dr Pierre Hubert, we are pleased to partner with Domain Therapeutics to develop our research, and launch PeptiMimesis on the road to success."

"Domain Therapeutics is ideally positioned to help bridge the gap between a breakthrough technology developed by a nascent company and the expectations of pharma partners. We strongly believe that our expertise will allow PeptiMimesis’ platform to deliver promising and valuable peptides to answer patient needs," said Pascal Neuville.

About therapeutic peptides
There are more than 60 US Food and Drug Administration (FDA) approved peptide medicines currently on the market. This is expected to grow significantly, with approximately 140 peptide drugs in clinical trials and more than 500 therapeutic peptides in preclinical development. In terms of value, the global peptide drug market is predicted to increase from $14.1Bn ( € 12.1Bn) in 2011 to an estimated $25.4Bn ( € 22.7Bn) in 2018, with an underlying increase in novel innovative peptide drugs from $8.6Bn ( € 7.7Bn) in 2011 (60%) to $17.0Bn ( € 15.2Bn) in 2018 (66%).

About transmembrane therapeutic peptides
Peptides possess key competitive advantages over antibodies such as a faster drug discovery process and a reduced manufacturing cost. In addition, the novel class of peptides developed by PeptiMimesis presents lower immunogenicity as they rapidly set within cellular membranes. The peptides also demonstrate an amplified therapeutic efficacy through indirect inhibition of multiple co – receptors and their associated signalling pathways. This innovative approach relies on the disruption of dimerization of membrane receptors using peptides that interfere with the transmembrane sites of oligomerization.

About PeptiMimesis
Created in October 2015, PeptiMimesis is a biopharmaceutical company based in Strasbourg, France dedicated to the development of transmembrane therapeutic peptides. The company’s proprietary platform delivers a set of drug candidates that act on strategic targets in the field of immuno-oncology, oncology and immune diseases. PeptiMimesis’ business model aims at moving forward internal assets up to a significant value inflexion point before out – licensing them to pharma partners. PeptiMimesis is also looking to establish partnerships on its unique technology with Pharma and Biotechs. www.pep timimesis.com

About Domain Therapeutics
Domain Therapeutics is a biopharmaceutical company based in Strasbourg, France and Montreal Canada. Domain is dedicated to the discovery and development of drugs targeting transmembrane receptors, including G Protein – Coupled Receptors (GPCRs), one of the most important classes of drug targets. Domain identifies and develops allosteric modulators and biased ligands through its innovative approach and its distinctive technologies. The company’s business model is to g enerate revenues through drug discovery partnerships while developing its own pipeline of drug candidates for central nervous system disorders and cancer. View Source